Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS)
CNY 8.35
(0.36%)
CNY 8.35
(0.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 44.23 Million CNY | 161.5% |
| 2022 | -71.92 Million CNY | -122.22% |
| 2021 | 323.75 Million CNY | 35.62% |
| 2020 | 238.72 Million CNY | 40.16% |
| 2019 | 170.33 Million CNY | 81.83% |
| 2018 | 93.67 Million CNY | 12.7% |
| 2017 | 83.11 Million CNY | 9.19% |
| 2016 | 76.12 Million CNY | 10.41% |
| 2015 | 68.94 Million CNY | 1.83% |
| 2014 | 67.7 Million CNY | 6.36% |
| 2013 | 63.65 Million CNY | 77.89% |
| 2012 | 35.78 Million CNY | -47.04% |
| 2011 | 67.56 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 10.61 Million CNY | -13.57% |
| 2024 Q3 | -13.92 Million CNY | -231.15% |
| 2024 Q1 | 12.28 Million CNY | 149.92% |
| 2023 Q3 | 4.04 Million CNY | -84.28% |
| 2023 Q4 | 4.91 Million CNY | 21.6% |
| 2023 FY | 44.23 Million CNY | 161.5% |
| 2023 Q1 | 9.56 Million CNY | 109.47% |
| 2023 Q2 | 25.7 Million CNY | 168.69% |
| 2022 Q4 | -101.07 Million CNY | -151.85% |
| 2022 Q3 | -40.13 Million CNY | -131.54% |
| 2022 Q2 | -17.33 Million CNY | -121.6% |
| 2022 Q1 | 80.24 Million CNY | -23.04% |
| 2022 FY | -71.92 Million CNY | -122.22% |
| 2021 Q3 | 63.84 Million CNY | -29.9% |
| 2021 FY | 323.75 Million CNY | 35.62% |
| 2021 Q1 | 64.57 Million CNY | 60.31% |
| 2021 Q2 | 91.07 Million CNY | 41.05% |
| 2021 Q4 | 104.25 Million CNY | 63.29% |
| 2020 Q1 | 45.65 Million CNY | 38.78% |
| 2020 Q3 | 58.76 Million CNY | -37.5% |
| 2020 FY | 238.72 Million CNY | 40.16% |
| 2020 Q2 | 94.03 Million CNY | 105.96% |
| 2020 Q4 | 40.27 Million CNY | -31.46% |
| 2019 Q2 | 52.29 Million CNY | 28.1% |
| 2019 FY | 170.33 Million CNY | 81.83% |
| 2019 Q4 | 32.89 Million CNY | -25.76% |
| 2019 Q3 | 44.31 Million CNY | -15.27% |
| 2019 Q1 | 40.82 Million CNY | 359.64% |
| 2018 Q2 | 42.81 Million CNY | 93.24% |
| 2018 Q1 | 22.15 Million CNY | 71.22% |
| 2018 FY | 93.67 Million CNY | 12.7% |
| 2018 Q4 | 8.88 Million CNY | -55.18% |
| 2018 Q3 | 19.81 Million CNY | -53.71% |
| 2017 FY | 83.11 Million CNY | 9.19% |
| 2017 Q2 | 26.43 Million CNY | -5.79% |
| 2017 Q3 | 15.68 Million CNY | -40.67% |
| 2017 Q4 | 12.94 Million CNY | -17.48% |
| 2017 Q1 | 28.05 Million CNY | 102.45% |
| 2016 Q3 | 15.52 Million CNY | -27.98% |
| 2016 Q2 | 21.55 Million CNY | -14.38% |
| 2016 Q4 | 13.85 Million CNY | -10.73% |
| 2016 FY | 76.12 Million CNY | 10.41% |
| 2016 Q1 | 25.17 Million CNY | 31.0% |
| 2015 Q1 | 34.4 Million CNY | 12.56% |
| 2015 FY | 68.94 Million CNY | 1.83% |
| 2015 Q4 | 19.21 Million CNY | 149.7% |
| 2015 Q3 | 7.69 Million CNY | 0.95% |
| 2015 Q2 | 7.62 Million CNY | -77.84% |
| 2014 Q4 | 30.56 Million CNY | 0.0% |
| 2014 FY | 67.7 Million CNY | 6.36% |
| 2013 FY | 63.65 Million CNY | 77.89% |
| 2012 FY | 35.78 Million CNY | -47.04% |
| 2011 FY | 67.56 Million CNY | 0.0% |